lum001

Cystic Fibrosis

Children's Hospital Los AngelesPhase 2/3Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 73/ 100

Competitive context

81 Active assets in the Cystic Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Tezacaftor Vertex Pharmaceuticals Incorporated	Phase 4	A
Liprotamase Anthera Pharmaceuticals	Phase 4	BBB
Lumacaftor Hospices Civils de Lyon	Phase 4	BBB
Ivacaftor Meyer Children's Hospital IRCCS	Phase 4	BBB
ELEXACAFTOR Meyer Children's Hospital IRCCS	Phase 4	BBB

View all 50 →

Same molecule, other indications

lum001 is also rated in:

Alagille syndromeDormant

BBB

Indicative ·

72 / 100

cholestasisDormant

BB

Indicative ·

64 / 100

progressive familial intrahepatic cholestasisDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.